Skip to main content
SpringerLink
Log in
SpringerLink
Log in

Prostate Cancer Prevention with 5 Alpha-Reductase Inhibitors

  • Chapter
  • First Online:
Clinical Cancer Prevention

Part of the book series: Recent Results in Cancer Research ((RECENTCANCER,volume 188))

Abstract

Testosterone gets converted into the more potent 5-[alpha]-dihydrotestosterone by 5-[alpha]- reductase. dihydrotestosterone (DHT) controls prostate mitotic activity and potentially prostate carcinogenesis. Interventions that inhibit 5-[alpha]-reductase have potential as preventive agents for prostate cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Andriole G, Bostwick D, Brawley O et al (2004) Chemoprevention of prostate cancer in men at high risk: rationale and design of the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial. J Urol 172(4 Pt 1):1314–1317

    Article  PubMed  CAS  Google Scholar 

  • Andriole GL, Humphrey PA, Serfling RJ, Grubb RL (2007) High-grade prostate cancer in the Prostate Cancer Prevention trial: fact or artifact? J Natl Cancer Inst 99:1355–1356

    Article  PubMed  Google Scholar 

  • Ankerst DP, Thompson IM (2006) Sensitivity and specificity of prostate-specific antigen for prostate cancer detection with high rates of biopsy verification. Arch Ital Urol Androl 78:125–129

    PubMed  Google Scholar 

  • Clark RV, Hermann DJ, Cunningham GR et al (2004) Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5 alpha-reductase inhibitor. J Clin Endocrinol Metab 89:2179–2184

    Article  PubMed  CAS  Google Scholar 

  • Cohen YC, Liu KS, Heyden NL et al (2007) Detection bias due to the effect of finasteride on prostate volume: a modeling approach for analysis of the Prostate Cancer Prevention trial. J Natl Cancer Inst 99:1366–1374, Patients treated with finasteride had a significantly smaller prostate volume resulting in a disproportionate sampling of the tumor during biopsy, allowing for increased identification of high-grade tumor

    Article  PubMed  CAS  Google Scholar 

  • Epstein JI, Walsh PC, Carmichael M, Brendler CB (1994) Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 271:368–374

    Article  PubMed  CAS  Google Scholar 

  • Epstein JI, Chan DW, Sokoll LJ et al (1998) Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings. J Urol 160(6 Pt 2):2407–2411

    PubMed  CAS  Google Scholar 

  • Etzioni RD, Howlader N, Shaw PA et al (2005) Long-term effects of finasteride on prostate specific antigen levels: results from the Prostate Cancer Prevention trial. J Urol 174:877–881

    Article  PubMed  CAS  Google Scholar 

  • Gronberg H (2003) Prostate cancer epidemiology. Lancet 361:859–864

    Article  PubMed  Google Scholar 

  • Grover S, Lowensteyn I, Hajek D et al (2006) Do the benefits of finasteride outweigh the risks in the Prostate Cancer Prevention trial? J Urol 175(3 Pt 1) :934–938, discussion 938 [Context Link]

    Google Scholar 

  • Jemal A, Siegel R, Ward E et al (2008) Cancer statistics, 2008. CA Cancer J Clin 58:71–96

    Article  PubMed  Google Scholar 

  • Lucia MS, Epstein JI, Goodman PJ et al (2007) Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention trial. J Natl Cancer Inst 99:1375–1383, Prostate volumes were lower and pathologic surrogates for tumor aggressiveness were lower with finasteride than with placebo. These results suggest that high-grade cancer was detected earlier and was less extensive in the finasteride group than in the placebo group

    Article  PubMed  CAS  Google Scholar 

  • Lucia MS, Darke AK, Goodman PJ et al (2008) Pathologic characteristics of cancers detected in the Prostate Cancer Prevention trial: implications for prostate cancer detection and chemoprevention. Cancer Prev Res 1:167–173, Men who developed prostate cancer on finasteride had a lower tumor volume and less aggressive disease across all tumor grades as compared with those in placebo arm

    Article  CAS  Google Scholar 

  • Majeed A, Babb P, Jones J, Quinn M (2000) Trends in prostate cancer incidence, mortality and survival in England and Wales 1971–1998. BJU Int 85:1058–1062

    Article  PubMed  CAS  Google Scholar 

  • McConnell JD, Wilson JD, George FW et al (1992) Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. J Clin Endocrinol Metab 74:505–508

    Article  PubMed  CAS  Google Scholar 

  • Moinpour CM, Darke AK, Donaldson GW et al (2007) Longitudinal analysis of sexual function reported by men in the Prostate Cancer Prevention trial. J Natl Cancer Inst 99:1025–1035, Finasteride had only a modest affect on sexual function and its impact diminished over time [Context Link]

    Article  PubMed  Google Scholar 

  • Pinsky P, Parnes HL, Ford L (2008) Estimating rates of true high-grade disease in the Prostate Cancer Prevention trial. Cancer Prev Res 1:182–186 [Context Link]

    Article  Google Scholar 

  • Redman MW, Tangen C, Goodman P et al (2008) Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach. Cancer Prev Res 1:174–181, Finasteride does not cause high-grade prostate cancer and reduces the risk of high-grade tumors by 27% and reduces the risk of low-grade tumors by 34%

    Article  CAS  Google Scholar 

  • Scardino PT (2003) The prevention of prostate cancer – the dilemma continues. N Engl J Med 349:297–299

    Article  PubMed  Google Scholar 

  • Thompson IM () Prostate cancer chemoprevention: update of the Prostate Cancer Prevention trial findings and implications for clinical practice. Curr Oncol Rep 10:529–532

    Google Scholar 

  • Thompson IM, Goodman PJ, Tangen CM et al (2003) The influence of finasteride on the development of prostate cancer. N Engl J Med 349:215–224

    Article  PubMed  CAS  Google Scholar 

  • Thompson IM, Chi C, Ankerst DP et al (2006) Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst 98:1128–1133

    Article  PubMed  CAS  Google Scholar 

  • Thompson IM, Tangen CM, Goodman PJ et al (2007) Finasteride improves the sensitivity of digital rectal examination for prostate cancer detection. J Urol 177:1749–1752, The sensitivity of DRE was significantly greater for cancer detection in men receiving finasteride than placebo (21.3 versus 16.7%, P = 0.015)

    Article  PubMed  CAS  Google Scholar 

  • Unger JM, LeBlanc M, Crowley JJ et al (2003) Estimating the impact of new clinical trial proven cancer therapy and cancer chemoprevention on population mortality: the Karnofsky Memorial lecture. J Clin Oncol 21(23 Suppl):246–252

    Article  Google Scholar 

  • Zeliadt SB, Etzioni RD, Penson DF et al (2005) Lifetime implications and cost-effectiveness of using finasteride to prevent prostate cancer. Am J Med 118:850–857

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Robotic Surgery, Department of Urology, University of Texas Health Sciences Center at San Antonio, San Antonio, TX, USA

    Dipen J. Parekh

Authors
  1. Dipen J. Parekh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dipen J. Parekh .

Editor information

Editors and Affiliations

  1. Prävention (ZeTuP), Zentrum für Tumordiagnostik und, Rorschacherstr. 150, St. Gallen, 9006, Switzerland

    Hans-Jörg Senn

  2. Prävention (ZeTuP), Zentrum für Tumordiagnostik und, Rorschacherstr. 150, St. Gallen, 9006, Switzerland

    Florian Otto

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer Berlin Heidelberg

About this chapter

Cite this chapter

Parekh, D.J. (2010). Prostate Cancer Prevention with 5 Alpha-Reductase Inhibitors. In: Senn, HJ., Otto, F. (eds) Clinical Cancer Prevention. Recent Results in Cancer Research, vol 188. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-10858-7_9

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-10858-7_9

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-10856-3

  • Online ISBN: 978-3-642-10858-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation